NP-010 Clinical and pharmacokinetic results after the switch to infliximab biosimilar in inflammatory bowel disease: 2 years of real-life experience

BackgroundDebate on the use of biosimilars focuses on the therapeutic efficacy and safety of switching between biosimilars and their reference products.PurposeTo determine the clinical results and pharmacokinetic behaviour of switching from originator infliximab to biosimilar in patients with inflammatory bowel disease (IBD) over 2 years.Materials and methodsProspective, longitudinal study (April 2017–March 2019). Patients with ulcerative colitis (UC) or Crohn’s disease (CD) treated with originator infliximab (Remicade) and changed to biosimilar (CT-P13) were included.The following outcome variables were defined: Clinical Remission (CR)= Harvey Bradshaw index